News | May 03, 2024
Moderna posts Q1 2024 revenues at US$167 million
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
2024 full-year revenue guidance raised by US$ 2 billion
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Dr Sheth's will commission a Healthmobile on Wheels initiative to ensure that healthcare doesn't remain confined to urban centers
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
‘Unmask Anemia’ aims to simplify assessment of iron deficiency anemia risk with an easy online self-test based on common signs and symptoms
Subscribe To Our Newsletter & Stay Updated
